TY - JOUR
T1 - Nano-bio interactions in mRNA nanomedicine
T2 - Challenges and opportunities for targeted mRNA delivery
AU - Saiding, Qimanguli
AU - Zhang, Zhongyang
AU - Chen, Shuying
AU - Xiao, Fan
AU - Chen, Yumeng
AU - Li, Yongjiang
AU - Zhen, Xueyan
AU - Khan, Muhammad Muzamil
AU - Chen, Wei
AU - Koo, Seyoung
AU - Kong, Na
AU - Tao, Wei
N1 - Publisher Copyright:
© 2023 Elsevier B.V.
PY - 2023
Y1 - 2023
N2 - Upon entering the biological milieu, nanomedicines swiftly interact with the surrounding tissue fluid, subsequently being enveloped by a dynamic interplay of biomacromolecules, such as carbohydrates, nucleic acids, and cellular metabolites, but with predominant serum proteins within the biological corona. A notable consequence of the protein corona phenomenon is the unintentional loss of targeting ligands initially designed to direct nanomedicines toward particular cells or organs within the in vivo environment. mRNA nanomedicine displays high demand for specific cell and tissue-targeted delivery to effectively transport mRNA molecules into target cells, where they can exert their therapeutic effects with utmost efficacy. In this review, focusing on the delivery systems and tissue-specific applications, we aim to update the nanomedicine population with the prevailing and still enigmatic paradigm of nano-bio interactions, a formidable hurdle in the pursuit of targeted mRNA delivery. We also elucidate the current impediments faced in mRNA therapeutics and, by contemplating prospective avenues—either to modulate the corona or to adopt an 'ally from adversary' approach—aim to chart a course for advancing mRNA nanomedicine.
AB - Upon entering the biological milieu, nanomedicines swiftly interact with the surrounding tissue fluid, subsequently being enveloped by a dynamic interplay of biomacromolecules, such as carbohydrates, nucleic acids, and cellular metabolites, but with predominant serum proteins within the biological corona. A notable consequence of the protein corona phenomenon is the unintentional loss of targeting ligands initially designed to direct nanomedicines toward particular cells or organs within the in vivo environment. mRNA nanomedicine displays high demand for specific cell and tissue-targeted delivery to effectively transport mRNA molecules into target cells, where they can exert their therapeutic effects with utmost efficacy. In this review, focusing on the delivery systems and tissue-specific applications, we aim to update the nanomedicine population with the prevailing and still enigmatic paradigm of nano-bio interactions, a formidable hurdle in the pursuit of targeted mRNA delivery. We also elucidate the current impediments faced in mRNA therapeutics and, by contemplating prospective avenues—either to modulate the corona or to adopt an 'ally from adversary' approach—aim to chart a course for advancing mRNA nanomedicine.
KW - mRNA nanomedicine
KW - Nano-bio interactions
KW - Protein corona
KW - Targeted delivery
U2 - 10.1016/j.addr.2023.115116
DO - 10.1016/j.addr.2023.115116
M3 - Review
C2 - 37871748
AN - SCOPUS:85177820287
SN - 0169-409X
VL - 203
JO - Advanced Drug Delivery Reviews
JF - Advanced Drug Delivery Reviews
M1 - 115116
ER -